| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | NTT5; Orphan sodium- and chloride-dependent neurotransmitter transporter NTT5; Solute carrier family 6 member 16 |
| Entrez GeneID | 28968; |
| WB Predicted band size | 82kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | KLH-conjugated synthetic peptide encompassing a sequence within the center region of human SLC6A16. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与SLC6A16抗体相关的文献示例(注：部分文献信息可能为模拟示例，实际引用时请核实原文准确性)：
---
1. **文献名称**: *SLC6A16 is a prognostic biomarker in glioblastoma and promotes tumor progression through mTOR signaling*
**作者**: Zhang Y, et al.
**摘要**: 该研究通过免疫组化(IHC)和Western blot技术，使用抗SLC6A16抗体检测其在胶质母细胞瘤组织中的高表达，发现SLC6A16通过激活mTOR通路促进肿瘤生长，并与患者不良预后相关。
2. **文献名称**: *Development and validation of a polyclonal antibody for detecting SLC6A16 in human tissues*
**作者**: Lee H, et al.
**摘要**: 本文报道了一种针对人SLC6A16蛋白的多克隆抗体的开发与验证。通过免疫印迹和免疫荧光实验，证明该抗体具有高特异性，适用于检测SLC6A16在正常及肿瘤组织中的亚细胞定位。
3. **文献名称**: *SLC6A16 as a novel therapeutic target in gastric cancer: Insights from antibody-based functional studies*
**作者**: Wang X, et al.
**摘要**: 研究利用抗SLC6A16抗体进行功能阻断实验，发现抑制SLC6A16可显著降低胃癌细胞的增殖和迁移能力，提示其作为潜在治疗靶点的价值。
---
**注意**：以上文献信息为示例性质，实际研究中建议通过PubMed或Web of Science等数据库，以关键词“SLC6A16 antibody”或“SLC6A16 immunohistochemistry”检索最新文献。若该基因研究较少，可扩展至其所属溶质载体家族(SLC6)相关研究。
The SLC6A16 antibody is a research tool designed to detect and analyze the solute carrier family 6 member 16 (SLC6A16) protein, a sodium-dependent transporter belonging to the SLC6 family. This protein, encoded by the *SLC6A16* gene, is implicated in the cellular uptake of neurotransmitters, amino acids, and osmolytes, though its precise physiological substrates remain under investigation. SLC6A16 is notably expressed in immune tissues, the thyroid, and certain cancers, suggesting roles in immune regulation, metabolic processes, and tumorigenesis. Studies highlight its upregulated expression in malignancies like gastric, lung, and thyroid cancers, linking it to cancer progression and potential therapeutic targeting.
The SLC6A16 antibody is widely utilized in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study protein localization, expression levels, and interactions in normal and diseased tissues. Its specificity and validation (e.g., knockout controls) are critical for reliable data. Current research explores SLC6A16's function in modulating immune responses, particularly in T-cells, and its role as a biomarker for cancer prognosis. However, challenges persist in fully elucidating its transport mechanisms and tissue-specific functions. This antibody thus serves as a vital reagent for advancing insights into SLC6A16's contributions to both physiology and pathology.
×
